Lukas Amler Selected Research

human TNFSF10 protein

11/2011	Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
3/2010	Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lukas Amler Research Topics

Disease

13	Neoplasms (Cancer) 10/2018 - 01/2006
9	Breast Neoplasms (Breast Cancer) 01/2018 - 01/2005
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2018 - 09/2007
3	Melanoma (Melanoma, Malignant) 01/2018 - 09/2007
2	Neoplasm Metastasis (Metastasis) 11/2011 - 01/2005
2	Lung Neoplasms (Lung Cancer) 10/2011 - 01/2006
1	Adrenal Gland Neoplasms (Adrenal Cancer) 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 10/2015
1	Colorectal Neoplasms (Colorectal Cancer) 03/2010
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2007
1	Papillary Carcinoma 01/2006
1	Carcinogenesis 01/2006

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 01/2018 - 09/2007
4	LigandsIBA 01/2018 - 01/2006
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 07/2009
3	Phosphotransferases (Kinase)IBA 06/2011 - 01/2006
2	atezolizumabIBA 10/2018 - 01/2018
2	Biological ProductsIBA 10/2018 - 02/2011
2	VemurafenibIBA 01/2018 - 09/2017
2	cobimetinibIBA 01/2018 - 09/2017
2	Messenger RNA (mRNA)IBA 09/2014 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 09/2014 - 12/2008
2	Trastuzumab (Herceptin)FDA Link 09/2012 - 02/2011
2	Immunoconjugates (Immunoconjugate)IBA 09/2012 - 02/2011
2	human ERBB2 proteinIBA 09/2012 - 02/2011
2	Ado-Trastuzumab EmtansineIBA 09/2012 - 02/2011
2	ErbB Receptors (EGF Receptor)IBA 09/2012 - 06/2011
2	human TNFSF10 proteinIBA 11/2011 - 03/2010
2	Death Domain ReceptorsIBA 10/2011 - 09/2007
2	Phenobarbital (Luminal)FDA Link 08/2011 - 06/2011
1	B7-H1 AntigenIBA 10/2018
1	EpiregulinIBA 09/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2014
1	onartuzumabIBA 09/2014
1	AmphiregulinIBA 09/2014
1	AnthracyclinesIBA 09/2012
1	taxaneIBA 09/2012
1	Lapatinib (GW572016)FDA Link 09/2012
1	Capecitabine (Xeloda)FDA Link 09/2012
1	Carboplatin (JM8)FDA LinkGeneric 11/2011
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2011
1	Bevacizumab (Avastin)FDA Link 11/2011
1	Small Interfering RNA (siRNA)IBA 10/2011
1	Transcription Factors (Transcription Factor)IBA 06/2011
1	MicroRNAs (MicroRNA)IBA 06/2011
1	Protein Kinases (Protein Kinase)IBA 06/2011
1	MitogensIBA 06/2011
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2011
1	EnzymesIBA 03/2010
1	Formaldehyde (Formol)FDA Link 03/2010
1	ParaffinIBA 03/2010
1	drozitumabIBA 03/2010
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2009
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2009
1	GlycosyltransferasesIBA 09/2007
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2006
1	tyrosine receptor (receptor, tyrosine)IBA 01/2006
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2006

Therapy/Procedure

7	Therapeutics 01/2017 - 01/2005
1	Immunotherapy 01/2017
1	Castration 10/2015
1	Drug Therapy (Chemotherapy) 02/2011